Correspondence 0001104659-23-103456 from Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635) (RNAZ)
Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635)
Date: Sept. 25, 2023 · CIK: 0001829635 · Accession: 0001104659-23-103456
AI Filing Summary & Sentiment
File numbers found in text: 333-274251
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Tim Buchmiller Withdrawal of Acceleration Request and Request for Acceleration of Effectiveness Registration Statement on Form S-1, as amended File No. 333-274251
Dear Mr. Buchmiller,
Reference is made to the letter of TransCode Therapeutics, Inc. (the “Company”), filed as correspondence via EDGAR on September 22, 2023, in which the Company requested the acceleration of the effective time and date of Company’s Registration Statement on Form S-1, as amended (File No. 333-274251) (the “Registration Statement”) to 5:00 p.m., Eastern time, on September 26, 2023. We are no longer requesting that such Registration Statement be declared effective at this specific date and time and we hereby formally withdraw such request for acceleration.
If you have any questions regarding this request, please contact Michael Bison and Finnbarr Murphy of Goodwin Procter LLP via telephone at (617) 570-1933 and (212) 459-7257 or via e-mail (MBison@goodwinlaw.com or FMurphy@goodwinlaw.com), respectively.
Sincerely,
TRANSCODE THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
VIA EDGAR
September 25, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re:
TransCode Therapeutics, Inc.
Withdrawal of Acceleration Request and
Request for Acceleration of Effectiveness
Registration Statement on Form S-1, as amended
File No. 333-274251
Dear Mr. Buchmiller,
Reference is made to the letter of TransCode Therapeutics, Inc.
(the “Company”), filed as correspondence via EDGAR on September 22, 2023, in which the Company requested the
acceleration of the effective time and date of Company’s Registration Statement on Form S-1, as amended (File No. 333-274251)
(the “Registration Statement”) to 5:00 p.m., Eastern time, on September 26, 2023. We are no longer requesting
that such Registration Statement be declared effective at this specific date and time and we hereby formally withdraw such request for
acceleration.
If you have any questions regarding this request,
please contact Michael Bison and Finnbarr Murphy of Goodwin Procter LLP via telephone at (617) 570-1933 and (212) 459-7257 or via e-mail
(MBison@goodwinlaw.com or FMurphy@goodwinlaw.com), respectively.
Sincerely,
TRANSCODE THERAPEUTICS, INC.
/s/ Robert Michael Dudley
Robert Michael Dudley
Chief Executive Officer
cc:
Thomas A. Fitzgerald, TransCode Therapeutics, Inc.
Michael Bison, Goodwin Procter LLP
Finnbarr Murphy, Goodwin Procter LLP